Skye Bioscience Inc (SKYE)

$1.21 -0.01 (-0.82%)
Market Cap 35.58M
Revenue (ttm) 0.00
Net Income (ttm) -26.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 164,905
Avg Vol 949,044
Day's Range N/A - N/A
Shares Out 32.06M
Stochastic %K 43%
Beta 2.68
Analysts Strong Sell
Price Target $8.71

Company Profile

Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in Jan...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 410 0266
Address:
11250 El Camino Real, Suite 100, San Diego, United States
Gesundheit
Gesundheit Dec. 4 at 8:49 PM
$SKYE Several good signs though. The company stated at March 2025 that funds should “allow us to fund our clinical trial for obesity through top-line Phase 2a data, complete process intensification manufacturing activities … and provide the ability to expand …” into 2027. and also a 513% increase in people buying calls.
0 · Reply
Gesundheit
Gesundheit Dec. 4 at 8:33 PM
$SKYE Hmmm tons of insider selling before the bad news. That could be a problem.
0 · Reply
11thestate
11thestate Dec. 4 at 3:31 PM
When we see a stock like this, we know how many damaged investors are out there. Believe it or not, there’s some good news. $SKYE investors — you might be surprised, but you actually have a chance to recover your losses. Don’t miss it. https://11th.com/cases/skye-investor-suit
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Dec. 4 at 1:40 PM
💎 LiquidTheta® Live Actionable Trade Asset: $SKYE Contracts: $SKYE June 18, 2026 $2 Calls Scale in: $0.30- $0.37 Scale out: $1.18-$2.03 Profit Potential : 240% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
HedgeAlerts
HedgeAlerts Dec. 4 at 6:59 AM
Hedge Alert Live - Protect Your Portfolio Contract: $SKYE $2.50 Put · DEC 19, 2025 Exp Entry Price: $1.30 - $1.65 Exit Price Target: $2.74 Profit Margin: +111% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
YazzJr
YazzJr Dec. 2 at 8:57 PM
$SKYE The slow bleed to under $1. Not looking good, at least short term. It's been two months since we received the news that SKYE's Nimicimab did not reach end points. That means they are going to require a higher dosage trial and a trial that examines more closes the combo'd effects. So two separate trials. I am a bit concerned that in two months, SKYE has been unable to secure a partner to perhaps help them with the trial costs. If SKYE has to run those two trials alone then their financial situation might be an issue. The longer this goes without SKYE having secured some kind of a partnership could mean that not many big pharma are interested in what SKYE has to offer. We will see. But right now things are looking a bit bleak. Let's hope that changes soon.
1 · Reply
YazzJr
YazzJr Dec. 2 at 7:47 PM
$SKYE The slow bleed to under $1 continues. It's been two months since the bad phase2A news and still no partnership or buyer. I am beginning to think there might not be any takers. Going into these further studies(Dosing and Combo therapy) alone is going to be financially challenging for SKYE. I know it's still early but, SKYE really needs some news here.
0 · Reply
Fellforit
Fellforit Dec. 2 at 6:53 PM
$SKYE
0 · Reply
Fellforit
Fellforit Dec. 2 at 6:50 PM
$SKYE
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Dec. 2 at 10:40 AM
💎 LiquidTheta® Live Actionable Trade Asset: $SKYE Contracts: $SKYE June 18, 2026 $2 Calls Scale in: $0.50- $0.61 Scale out: $1.94-$3.33 Profit Potential : 188% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
Latest News on SKYE
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Dec 4, 2025, 10:55 AM EST - 7 hours ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

SKYE INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Dec 3, 2025, 9:51 AM EST - 1 day ago

SKYE INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Nov 28, 2025, 11:08 AM EST - 6 days ago

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Skye Bioscience to Participate in Upcoming Investment Conferences

Nov 24, 2025, 7:00 AM EST - 10 days ago

Skye Bioscience to Participate in Upcoming Investment Conferences

Skye Bioscience, Inc. (SKYE) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 10:41 PM EST - 23 days ago

Skye Bioscience, Inc. (SKYE) Q3 2025 Earnings Call Transcript

Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update

Nov 10, 2025, 4:01 PM EST - 24 days ago

Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update

Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain

Nov 5, 2025, 7:05 AM EST - 4 weeks ago

Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain

Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025

Nov 5, 2025, 7:00 AM EST - 4 weeks ago

Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025

Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer

Oct 28, 2025, 8:00 AM EDT - 5 weeks ago

Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer

CNTX

Skye Bioscience, Inc. - Special Call

Oct 6, 2025, 2:25 PM EDT - 2 months ago

Skye Bioscience, Inc. - Special Call

Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge

Oct 6, 2025, 1:09 PM EDT - 2 months ago

Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge

Skye Bioscience's Investigational Drug Disappoints As Monotherapy For Weight Loss

Oct 6, 2025, 10:39 AM EDT - 2 months ago

Skye Bioscience's Investigational Drug Disappoints As Monotherapy For Weight Loss

Skye Bioscience's obesity drug fails to meet main goal of mid-stage study

Oct 6, 2025, 7:09 AM EDT - 2 months ago

Skye Bioscience's obesity drug fails to meet main goal of mid-stage study

Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial

Oct 6, 2025, 7:00 AM EDT - 2 months ago

Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial

Skye Bioscience: Promising Nimacimab Data Supports Buy Rating

Oct 1, 2025, 10:45 AM EDT - 2 months ago

Skye Bioscience: Promising Nimacimab Data Supports Buy Rating

Could This New Drug Be The Safer Way To Fight Obesity?

Sep 19, 2025, 2:19 PM EDT - 2 months ago

Could This New Drug Be The Safer Way To Fight Obesity?

Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting

Sep 19, 2025, 7:00 AM EDT - 2 months ago

Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting

Skye Bioscience, Inc. (SKYE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 9:45 AM EDT - 3 months ago

Skye Bioscience, Inc. (SKYE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data

Sep 5, 2025, 1:35 PM EDT - 3 months ago

Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data

Skye Bioscience, Inc. (SKYE) Virtual KOL Event Transcript

Sep 5, 2025, 1:30 AM EDT - 3 months ago

Skye Bioscience, Inc. (SKYE) Virtual KOL Event Transcript

Skye's CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model

Sep 4, 2025, 7:00 AM EDT - 3 months ago

Skye's CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model

Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study

Sep 2, 2025, 7:00 AM EDT - 3 months ago

Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study

Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout

Aug 27, 2025, 7:00 AM EDT - 3 months ago

Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout

Skye Bioscience to Participate in Upcoming Investment and Medical Conferences

Aug 21, 2025, 7:00 AM EDT - 3 months ago

Skye Bioscience to Participate in Upcoming Investment and Medical Conferences

Skye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 8:36 PM EDT - 4 months ago

Skye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call Transcript

Skye (SKYE) Q2 R&D Soars 249% No Revenue

Aug 7, 2025, 4:28 PM EDT - 4 months ago

Skye (SKYE) Q2 R&D Soars 249% No Revenue

Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update

Aug 7, 2025, 4:01 PM EDT - 4 months ago

Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

Jul 30, 2025, 7:00 AM EDT - 4 months ago

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab Dosing

Jul 7, 2025, 11:59 PM EDT - 5 months ago

Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab Dosing

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions

Jun 23, 2025, 7:00 AM EDT - 5 months ago

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions

Jun 17, 2025, 7:00 AM EDT - 6 months ago

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions

Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab

May 19, 2025, 5:00 AM EDT - 7 months ago

Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 13, 2025, 4:05 PM EDT - 7 months ago

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity

May 13, 2025, 7:00 AM EDT - 7 months ago

Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity

Skye Bioscience, Inc. (SKYE) Q1 2025 Earnings Call Transcript

May 9, 2025, 7:20 PM EDT - 7 months ago

Skye Bioscience, Inc. (SKYE) Q1 2025 Earnings Call Transcript

Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity

May 8, 2025, 4:01 PM EDT - 7 months ago

Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity

Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025

May 7, 2025, 7:00 AM EDT - 7 months ago

Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025

Skye Bioscience to Participate in May Investment and Medical Conferences

Apr 29, 2025, 7:00 AM EDT - 7 months ago

Skye Bioscience to Participate in May Investment and Medical Conferences

A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value

Apr 16, 2025, 7:50 AM EDT - 8 months ago

A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value

Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models

Apr 15, 2025, 3:42 PM EDT - 8 months ago

Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models

LLY

Gesundheit
Gesundheit Dec. 4 at 8:49 PM
$SKYE Several good signs though. The company stated at March 2025 that funds should “allow us to fund our clinical trial for obesity through top-line Phase 2a data, complete process intensification manufacturing activities … and provide the ability to expand …” into 2027. and also a 513% increase in people buying calls.
0 · Reply
Gesundheit
Gesundheit Dec. 4 at 8:33 PM
$SKYE Hmmm tons of insider selling before the bad news. That could be a problem.
0 · Reply
11thestate
11thestate Dec. 4 at 3:31 PM
When we see a stock like this, we know how many damaged investors are out there. Believe it or not, there’s some good news. $SKYE investors — you might be surprised, but you actually have a chance to recover your losses. Don’t miss it. https://11th.com/cases/skye-investor-suit
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Dec. 4 at 1:40 PM
💎 LiquidTheta® Live Actionable Trade Asset: $SKYE Contracts: $SKYE June 18, 2026 $2 Calls Scale in: $0.30- $0.37 Scale out: $1.18-$2.03 Profit Potential : 240% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
HedgeAlerts
HedgeAlerts Dec. 4 at 6:59 AM
Hedge Alert Live - Protect Your Portfolio Contract: $SKYE $2.50 Put · DEC 19, 2025 Exp Entry Price: $1.30 - $1.65 Exit Price Target: $2.74 Profit Margin: +111% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
YazzJr
YazzJr Dec. 2 at 8:57 PM
$SKYE The slow bleed to under $1. Not looking good, at least short term. It's been two months since we received the news that SKYE's Nimicimab did not reach end points. That means they are going to require a higher dosage trial and a trial that examines more closes the combo'd effects. So two separate trials. I am a bit concerned that in two months, SKYE has been unable to secure a partner to perhaps help them with the trial costs. If SKYE has to run those two trials alone then their financial situation might be an issue. The longer this goes without SKYE having secured some kind of a partnership could mean that not many big pharma are interested in what SKYE has to offer. We will see. But right now things are looking a bit bleak. Let's hope that changes soon.
1 · Reply
YazzJr
YazzJr Dec. 2 at 7:47 PM
$SKYE The slow bleed to under $1 continues. It's been two months since the bad phase2A news and still no partnership or buyer. I am beginning to think there might not be any takers. Going into these further studies(Dosing and Combo therapy) alone is going to be financially challenging for SKYE. I know it's still early but, SKYE really needs some news here.
0 · Reply
Fellforit
Fellforit Dec. 2 at 6:53 PM
$SKYE
0 · Reply
Fellforit
Fellforit Dec. 2 at 6:50 PM
$SKYE
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Dec. 2 at 10:40 AM
💎 LiquidTheta® Live Actionable Trade Asset: $SKYE Contracts: $SKYE June 18, 2026 $2 Calls Scale in: $0.50- $0.61 Scale out: $1.94-$3.33 Profit Potential : 188% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
HedgeAlerts
HedgeAlerts Dec. 1 at 9:52 PM
Hedge Alert Live - Protect Your Portfolio Contract: $SKYE $2.50 Put · DEC 19, 2025 Exp Entry Price: $1.00 - $3.90 Exit Price Target: $1.55 Profit Margin: +55% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
11thestate
11thestate Dec. 1 at 3:55 PM
When we see a stock like this, we know how many damaged investors are out there. Believe it or not, there’s some good news. $SKYE investors — you might be surprised, but you actually have a chance to recover your losses. Don’t miss it. https://11th.com/cases/skye-investor-suit
0 · Reply
Lagomambo5
Lagomambo5 Dec. 1 at 11:27 AM
$SKYE
0 · Reply
YazzJr
YazzJr Nov. 26 at 1:37 PM
$SKYE I think it's going to be harder and harder for SKYE to find their way with Nimicimab. Looks like all the big pharma's are going the oral route with their obesity meds including NOVO. Interesting article on Seeking Alpha. https://seekingalpha.com/article/4847591-novo-nordisk-forget-about-alzheimers-the-real-catalyst-is-the-wegovy-pill
2 · Reply
Iightning
Iightning Nov. 26 at 6:06 AM
1ightning® Options Trade Alert (Actionable) | Buy $SKYE Dec 19 $2 Call | Enter: $0.05 Exit: $0.09 | Profit: 71.51% ROI | https://1ightning.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 26 at 2:07 AM
Hedge Alert Live - Protect Your Portfolio Contract: $SKYE $2.50 Put · DEC 19, 2025 Exp Entry Price: $1.00 - $2.00 Exit Price Target: $1.52 Profit Margin: +52% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Iightning
Iightning Nov. 25 at 4:15 PM
1ightning® Options Trade Alert (Actionable) | Buy $SKYE Dec 19 $2 Call | Enter: $0.05 Exit: $0.09 | Profit: 71.51% ROI | https://1ightning.com
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 25 at 12:30 PM
💎 LiquidTheta® Live Actionable Trade Asset: $SKYE Contracts: $SKYE June 18, 2026 $2 Calls Scale in: $0.50- $0.61 Scale out: $1.94-$3.33 Profit Potential : 55% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
Iightning
Iightning Nov. 25 at 5:09 AM
1ightning® Options Trade Alert (Actionable) | Buy $SKYE Dec 19 $2 Call | Enter: $0.05 Exit: $0.09 | Profit: 71.51% ROI | https://1ightning.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 25 at 2:09 AM
Hedge Alert Live - Protect Your Portfolio Contract: $SKYE $2.50 Put · DEC 19, 2025 Exp Entry Price: $1.00 - $1.60 Exit Price Target: $2.08 Profit Margin: +108% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
newsfile_corp
newsfile_corp Nov. 24 at 12:00 PM
https://nfne.ws/275680 $SKYE #Chemicals #Pharmaceutical #Biotechnology #Cannabis #Marijuana #MarijuanaStocks #Medical #Pharmaceuticals #Pot
1 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 23 at 6:36 PM
💎 LiquidTheta® Live Actionable Trade Asset: $SKYE Contracts: $SKYE June 18, 2026 $2 Calls Scale in: $0.52- $0.64 Scale out: $2.03-$3.48 Profit Potential : 242% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply